Czech university hospital providing clinical validation sites for cardiac AI and digital health technologies in EU research consortia.
Fakultní nemocnice Olomouc (FNO) is a major Czech university hospital providing tertiary-level clinical care alongside research and teaching functions in affiliation with Palacký University. In EU-funded projects, FNO contributes as a clinical implementation site — providing real patient cohorts, medical expertise, and real-world validation environments that pure research institutions cannot offer. Their H2020 participation spans digital health platforms for elderly patients and cardiological risk stratification, where they bring the clinical weight of an operating hospital to technology validation. They are a specialist contributor rather than a project driver, embedding new diagnostic or care technologies into live hospital workflows.
PROFID (2020–2026) targets personalised risk prediction and prevention of sudden cardiac death after myocardial infarction, with FNO providing clinical expertise and patient access.
PROFID explicitly focuses on building a clinical decision tool for post-MI populations, positioning FNO as a validation and deployment partner.
SHAPES (2019–2023) deployed smart and healthy ageing systems emphasising connectivity, interoperability, and community participation, with FNO as a clinical site.
Both projects are Innovation Actions — the EU funding type specifically for implementation and demonstration — confirming FNO's role as a site for real-world technology deployment rather than basic research.
FNO entered H2020 through SHAPES (2019), a broad digital health platform for ageing that centred on connectivity, interoperability, and community access — technology-infrastructure themes common to large-scale eHealth consortia. Their second project, PROFID (2020), marks a clear shift toward specific clinical cardiology: sudden cardiac death, post-myocardial infarction care, and personalised risk prediction tools. The trajectory moves from general digital health participation toward high-stakes, condition-specific clinical AI — a narrowing and deepening of focus rather than diversification.
FNO is moving toward precision cardiology and AI-assisted clinical decision-making, suggesting future collaboration appetite in cardiac digital twins, post-MI monitoring, or wearable-to-clinic data pipelines.
FNO has participated exclusively as a consortium partner across both projects and has not coordinated any H2020 grant, consistent with the profile of a clinical site that joins large consortia to provide patient access and implementation capacity. Their 61 unique partners across 19 countries from just 2 projects indicates participation in very large, pan-European consortia — SHAPES alone was a 35+ partner initiative. This suggests working with FNO means joining a network where they are one of several clinical validation nodes, not the administrative or scientific lead.
FNO has built connections with 61 distinct organisations across 19 countries despite only two projects, reflecting their involvement in large-scale EU consortia. Their network spans Western and Central Europe, with no identified geographic concentration beyond Czech Republic.
FNO is one of relatively few Central European university hospitals with demonstrated H2020 Innovation Action experience, making them a credible clinical validation partner for health technology developers seeking real-world deployment sites in the Czech Republic and the broader CEE region. Their specific combination of ageing-related digital health and acute cardiology expertise is uncommon — most clinical partners specialise in one or the other — giving them unusual versatility for consortium builders working at the intersection of chronic disease management and acute cardiac events. Any project requiring actual hospital deployment, ethical approval infrastructure, and live patient cohorts in CZ has a ready partner here.
